Skip Navigation


Cardiovascular Research Advance Access originally published online on September 10, 2009
Cardiovascular Research 2009 84(2):178-179; doi:10.1093/cvr/cvp307
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
84/2/178    most recent
cvp307v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Muller-Delp, J. M.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Muller-Delp, J. M.
Related Collections
Right arrowRelated Article
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2009. For permissions please email: journals.permissions@oxfordjournals.org.

Ascorbic acid and tetrahydrobiopterin: looking beyond nitric oxide bioavailability

Judy M. Muller-Delp*

Department of Physiology and Functional Genomics, University of Florida, PO Box 100274, 1600 SW Archer Road, Gainesville, FL 32610, USA

* Corresponding author. Tel: +1 352 392 3791; fax: +1 352 846 0270. E-mail address: jdelp@ufl.edu

This editorial refers to ‘Ascorbic acid and tetrahydrobiopterin potentiate the EDHF phenomenon by generating hydrogen peroxide’ by A. Garry et al., pp. 218–226, this issue.

The first 10% of the full text of this article appears below.

Endothelial dysfunction, manifested as reduced vasodilatory capacity, occurs in arteries exposed chronically to cardiovascular risk factors.1 Hyperglycaemia, hypercholesterolaemia, hypertension, ageing, and smoking have all been associated with endothelial dysfunction.2–4 Although the molecular basis of endothelial dysfunction remains incompletely understood, numerous studies support a loss of bioavailable nitric oxide (NO) as a key mechanism underlying the dysfunction.1,4 Both tetrahydrobiopterin (BH4) and ascorbic acid play a role in sustaining NO bioavailabilty,5–7 and supplementation with either BH4 or ascorbic acid has been shown to improve endothelial function in humans and in animal models.6,8,9 As a result, investigations of the cardiovascular implications of treatment with exogenous BH4 . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related Article

Ascorbic acid and tetrahydrobiopterin potentiate the EDHF phenomenon by generating hydrogen peroxide
Ambroise Garry, David H. Edwards, Ian F. Fallis, Robert L. Jenkins, and Tudor M. Griffith
Cardiovasc Res 2009 84: 218-226. [Abstract] [Full Text] [PDF]